Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on May 9, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell

This study compared two chemotherapy combinations – R-DHAP and R-DHAOx – to see which caused less kidney damage in patients with non-Hodgkin lymphoma (NHL). The results showed that fewer patients receiving R-DHAOx developed poor kidney function than patients receiving R-DHAP.

Some background

Combinations of chemotherapy drugs are often used to treat patients with non-Hodgkin lymphoma (NHL). Different combinations cause different side effects, such as kidney damage. It is important to prevent kidney damage in patients with a higher risk of kidney problems. 

R-DHAP (rituximab, cisplatin, dexamethasone, and cytarabine) is a standard chemotherapy combination for NHL. However, it can cause kidney side effects in patients. Cisplatin (Platinol) is replaced with oxaliplatin (Eloxatin) in the R-DHAOx combination to reduce kidney damage. It is important to confirm that R-DHAOx protects patients from kidney damage compared to R-DHAP.

Methods & findings

Data from 58 patients with NHL were analyzed. 35 patients received R-DHAOx and 23 received R-DHAP.  

After 1 cycle, side effects in the kidney were reported in 68% of patients who received R-DHAP and 7.7% of patients who received R-DHAOx. 6 patients in the R-DHAP group switched to R-DHAOx because of kidney side effects.

Both chemotherapy combinations gave similar results. 36.4% of patients receiving R-DHAP and 40% of patients receiving R-DHAOx had no sign of cancer by the end of treatment. 22.7% of patients receiving R-DHAP and 25.7% of patients receiving R-DHAOx had a significant reduction in cancer by the end of treatment.

Similar numbers of patients experienced other side effects in both treatment groups. 66% of patients receiving R-DHAP and 63.7% of patients receiving R-DHAOx developed severe blood-related side effects. 61.2% of patients receiving R-DHAP and 43.3% of patients receiving R-DHAOx required a blood transfusion.

The bottom line

The authors concluded that R-DHAOx causes fewer kidney side effects compared to R-DHAP. in patients with NHL

The fine print

This study used data from medical records and patients who received R-DHAP did so earlier than R-DHAOx. This may mean that treatment doses have improved in the meantime. 

Published By :

European Journal of Haematology

Date :

Apr 17, 2020

Original Title :

R-DHA-oxaliplatin (R-DHAOx) versus R-DHA-cisplatin (R-DHAP) regimen in B-cell lymphoma treatment.

click here to get personalized updates